IQVIA Veeva Clinical Operations Expansion: IQVIA Selects Veeva CTMS, eTMF, Study Startup and Site Connect as Enterprise Standards

iqvia news

IQVIA and Veeva Systems have expanded their partnership. IQVIA Veeva clinical operations now includes Veeva CTMS, eTMF, Study Startup and Site Connect as enterprise standard applications across IQVIA clinical development studies, extending the earlier EDC partnership.

IQVIA Launches IQVIA Life Science Models at TechIQ 2026 to Help Life Sciences Companies Predict Clinical Trial Outcomes

iqvia news

IQVIA Life Science Models were introduced at TechIQ 2026 to help life sciences companies predict clinical trial outcomes. IQVIA reports that 85% of predictions across 50 trials and 270 endpoints were on target or clinically close.

Merck SPR2015 KRAS G12D Inhibitor Deal Strengthens Oncology Pipeline Through $2.13 Billion Agreement

Merck MSD

Merck has entered into an exclusive global licensing agreement with SciBrunch Therapeutics for SPR2015, a preclinical oral KRAS G12D inhibitor, in a transaction valued at up to $2.13 billion, including a $400 million upfront payment.

IQVIA Predictive Clinical Development Cuts Trial Delays With AI-Powered Approach

iqvia news

IQVIA has launched IQVIA Predictive Clinical Development, an AI-powered platform built with Anthropic, AWS, Databricks, Microsoft, NVIDIA, Palantir and Snowflake, designed to help sponsors bring new therapies to market up to two years faster.

Charles River Laboratories Q2 2026 Earnings: Revenue Hits $1.00 Billion as Company Raises Full-Year Guidance

Charles_River_Laboratories news and statistics

Charles River Laboratories (NYSE: CRL) posted Q2 2026 revenue of $1.00 billion and non-GAAP EPS of $3.02, then raised full-year guidance on strengthening DSA demand and Manufacturing outperformance, even as GAAP results absorbed a one-time loss from its CDMO and Cell Solutions divestiture.

Charles River NGS Services Power Arovella Therapeutics’ ALA-101 Cell Therapy Manufacturing

Charles_River_Laboratories news and statistics

Charles River Laboratories will supply GMP-grade Next Generation Sequencing (NGS) and viral safety release testing to Arovella Therapeutics for its ALA-101 CAR-iNKT cell therapy. The tie-up follows FDA acceptance of NGS-based viral safety testing in Arovella’s IND for treating CD19+ B-cell lymphomas and leukemias.